Navigation Links
Celsion Receives COMP Recommendation for Orphan Drug Designation in Europe for ThermoDox® to Treat Primary Liver Cancer
Date:11/11/2010

ctive for larger tumors. There are few non-surgical therapeutic treatment options available as radiation therapy and chemotherapy are largely ineffective in the treatment of primary liver cancer.

About ThermoDox® and the Phase III HEAT StudyThermoDox® is a proprietary heat-activated liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers.  In the HEAT study, ThermoDox® is administered intravenously in combination with RFA.  Localized mild hyperthermia (39.5-42 degrees Celsius) created by the RFA releases the entrapped doxorubicin from the liposome. This delivery technology enables high concentrations of doxorubicin to be deposited preferentially in a targeted tumor.

For primary liver cancer, ThermoDox® is being evaluated in a 600 patient global Phase III study at 76 clinical sites under an FDA Special Protocol Assessment. The study is designed to evaluate the efficacy of ThermoDox® in combination with RFA when compared to patients who receive RFA alone as the control. The primary endpoint for the study is progression-free survival (PFS) with a secondary confirmatory endpoint of overall survival.  A pre-planned, unblinded interim efficacy analysis will be performed by the independent Data Monitoring Committee when enrollment in the trial is complete and 190 PFS events are realized in the study population.  Additional information on the Company's ThermoDox® clinical studies may be found at http://www.clinicaltrials.gov

About CelsionCelsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs including tumor-targeting treatments using focused heat energy in combination wit
'/>"/>

SOURCE Celsion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Celsion Announces ThermoDoxs Prominence in Abstracts Presented at the 2nd International MR-Guided Ultrasound Symposium
2. Data Monitoring Committee Unanimously Recommends Continuation of Celsions Phase III ThermoDox® HEAT Study to Treat Primary Liver Cancer
3. Celsion Receives SBIR Grant To Expand Its Technology Platform
4. Celsion Receives Fast Track Designation for ThermoDox® Development Program to Treat Primary Liver Cancer
5. Celsion Announces CFO Departure
6. Stereotaxis Receives Commitment to Increase and Extend Credit Facility
7. Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards
8. CMUs Bone Tissue Engineering Center Receives Defense Department Research Grant to Help Injured Soldiers
9. AccuVein Receives Grant for its Award Winning AV300 Vein Illumination System
10. Cocrystal Discovery Receives Awards for Its Novel Antiviral Drug Development Programs
11. DNA Medicine Institute Receives Qualifying Therapeutic Discovery Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... that address unmet medical needs in the areas ... has completed enrollment of the additional subjects, as ... this year, into the company,s Phase 2 study ... regulator (IDR) and is being evaluated as a ...
(Date:8/31/2015)... August 31, 2015 Premune ... into an exclusive licensing agreement for Redonyl ® ... $300 million USD veterinary dermatology market, is a nutritional ... support healthy skin in dogs and cats. Redonyl ® ... , and has been received positively in the ...
(Date:8/31/2015)... Aug. 31, 2015 Bionomics Limited (ASX:BNO, ADR:BMICY), ... of innovative therapeutics for the treatment of diseases of ... that its BNC101 IND submission has passed review by ... to initiate a Phase 1 clinical trial in patients ... pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Premune Broadens Portfolio With Novel Innovet Skin Health Product 2Premune Broadens Portfolio With Novel Innovet Skin Health Product 3Premune Broadens Portfolio With Novel Innovet Skin Health Product 4Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... ATS Medical, Inc. (Nasdaq: ATSI ), manufacturer and ... it will participate in the 2009 Canaccord Adams Cardiovascular ... Dale, President and CEO of ATS Medical, will present ... 2009. , (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ) , Attendance at ...
... 3 Robert Mazzacavallo has joined Veridiam as the ... contract manufacturer of high-precision, fabricated assemblies and metal components, ... power generation, aerospace and general industrial markets. , Before ... Industries in Camas, WA. At C-Tech, Bob worked ...
Cached Medicine Technology:ATS Medical to Participate in the 2009 Canaccord Adams Cardiovascular Conference 2Veridiam Names Robert Mazzacavallo New CFO 2
(Date:8/31/2015)... CA (PRWEB) , ... August 31, 2015 , ... Patients ... from and those who are interested in learning more about the procedure beyond the ... Mohebi. , Internationally recognized hair transplant surgeon Parsa Mohebi will be on hand ...
(Date:8/31/2015)... ... 31, 2015 , ... The Sundance Film Festival award winning documentary “Alive Inside” ... Inside” shadows a social worker who advocates for the use of music therapy for ... music to residents in health care centers who may have lost a spark in ...
(Date:8/31/2015)... ... August 31, 2015 , ... Garden ... in 2008, the result of a merger of five of the busiest urology ... they could provide more cost-effective and higher quality care than they did individually. ...
(Date:8/31/2015)... ... 2015 , ... NJ Top Docs Presents, Dr. Michael Betsy! Dr. Betsy has been reviewed ... Dr. Michael Betsy graduated from Don Bosco Prep in 1990 and was Class Salutatorian. ... both sports in his senior year. He was inducted into the National Honor Society ...
(Date:8/31/2015)... TN (PRWEB) , ... August 31, 2015 , ... ... how it may be prevented during Amblyopia Awareness Month. Only a comprehensive eye examination ... the most common cause of visual impairment among children, affecting approximately 2 to 3 ...
Breaking Medicine News(10 mins):Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2Health News:Public Invited to Dementia Documentary Screening at North Carolina Retirement Community 2Health News:NJ Top Docs Presents, Garden State Urology! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3
... Serena Gordon HealthDay Reporter , THURSDAY, Jan. 13 ... SAT that,s got your teen,s stomach tied up in knots, ... scores. New research, published in the Jan. 14 issue ... minutes writing about their test anxiety and fears just before ...
... Drugs that pharmaceutical companies market most aggressively to physicians and ... most patients a phenomenon described as the "inverse benefit ... Branch at Galveston. Published online Thursday, Jan. 13 ... article explores recent withdrawals of blockbuster drugs due to safety ...
... (MGH) Cancer Center researchers have discovered a previously unknown feature ... sequences that do not code for proteins. These DNA ... their role in chromosomal structure but previously were not suspected ... appear in the journal Science and is receiving ...
... , THURSDAY, Jan. 13 (HealthDay News) -- In an unscripted ... Tucson and America" memorial, President Barack Obama said Rep. Gabrielle ... and her husband Mark Kelly at University Medical Center in ... to House Minority Leader Nancy Pelosi (D-Calif.) confirmed that Pelosi, ...
... and reconstructed the genomes of most of the ... and documented how the microbe populations changed over ... eventually help researchers understand the causes of various ... sometimes fatal necrotizing enterocolitis, according to researchers at ...
... programs that put them behind the wheelin a driving simulator, ... the conclusion of a new article published in Current ... for Psychological Science. Older people are at much ... and provinces test older drivers, hoping to get the riskiest ...
Cached Medicine News:Health News:Write Your Test Stress Away 2Health News:Write Your Test Stress Away 3Health News:Inverse benefits due to drug marketing undermine patient safety and public health 2Health News:Inverse benefits due to drug marketing undermine patient safety and public health 3Health News:Overexpression of repetitive DNA sequences discovered in common tumor cells 2Health News:Giffords Opens Eyes. Like 'Watching a Miracle,' Friends Say 2Health News:Giffords Opens Eyes. Like 'Watching a Miracle,' Friends Say 3Health News:Scientists sequence gut microbes of premature infant 2Health News:Scientists sequence gut microbes of premature infant 3Health News:Scientists sequence gut microbes of premature infant 4Health News:Scientists sequence gut microbes of premature infant 5Health News:Driving simulators help older adults improve their road skills 2
... Artemis is the world's first very high ... 3D Arc-scanning technology, Artemis provides microscopic resolution ... cornea and anterior segments of the human ... (VHF) ultrasound eye scanner. In use, the ...
The UD-6000 combines all the functions of modern ultrasound diagnostics used in ophthalmology: The latest generation high resolution A/B-sector scanner, a diagnostic A-mode scanner with an optional p...
... is a sensitive B-scan system which quickly identifies ... of both eyes differ by more than 0.3 ... be suspected. The B5500 enables quick and easy ... water bath or inserting shells under the lids. ...
... CineScan A/B represent a true breakthrough in ... with technology and diagnostic capability previously unavailable. ... vitreous. Adjust the gain up to 105db ... invisible at a standard 90db setting - ...
Medicine Products: